Olema Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Olema Pharmaceuticals, Inc. | OLMA - NASDAQ |
$16.00-$18.00 | $19.00 | $45.00 | 11 million | 11/19/2020 |
| J.P. Morgan, Jefferies, Cowen, Canaccord Genuity ​ | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-30 Terms Added 2020-11-16 | ||||||
Olema Pharmaceuticals, Inc. Quote & Chart - Click for current quote - OLMA
IPO Boutique aggregates information on public companies and private companies, such as "OLMA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Olema Pharmaceuticals, Inc. (adapted from Olema Pharmaceuticals, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted therapies for women’s cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted therapies for women’s cancers.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "OLMA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.